DRMA
Dermata Therapeutics Inc
NASDAQ: DRMA · HEALTHCARE · BIOTECHNOLOGY
$1.02
-4.67% today
Updated 2026-10-09
Market cap
$5.30M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.39
Dividend yield
—
52W range
$1 – $4
Volume
0.9M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.8
Quality
C3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-13.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →274 stocks currently score above 75
Price targets
Analyst target
$4.00
+292.16%
12-Month target
$1.37
+34.31%
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -13.07 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.53M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-9.61M | $-7.79M | $-12.29M | $-7.56M | $-2.97M |
| EPS | — | — | — | — | $-4.39 |
| Free cash flow | $-8.83M | $-6.41M | $-11.16M | $-7.76M | $-2.53M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Dermata Therapeutics Inc trades at $1.02. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -13.07, it sits in the distress.
Frequently asked questions
What is Dermata Therapeutics Inc's stock price?
Dermata Therapeutics Inc (DRMA) trades at $1.02.
Is Dermata Therapeutics Inc overvalued?
Dermata Therapeutics Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Dermata Therapeutics Inc (DRMA)?
The 12-month analyst consensus target is $4.00, about 292.2% above the current $1.02. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Dermata Therapeutics Inc's Altman Z-Score is -13.07, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-110.75%
Beta0.66
50D MA$1.24
200D MA$1.42
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—